PDF(Pubmed)
Abstract：
BACKGROUND: The study aimed to investigate novel biomarkers from the C1q TNF superfamily and evaluate their role in autoimmune inflammatory rheumatic diseases with the goal of identifying an effective biomarker to measure clinical disease activity and assess treatment efficacy.
METHODS: Sixty-one Axial spondyloarthritis (AxSpa) patients and 30 healthy controls were enrolled in the study. The serum biomarkers subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α and the disease indices BASDAI, BASFI, MASES, and ASDAS-ESR/CRP were evaluated and compared. The patients were then classified, and their serum biomarkers were assessed according to their ASDAS scores and their treatment regimens.
RESULTS: Among the studied biomarkers, none showed a significant difference between the patients and the healthy controls. Although the difference was not statistically significant, the median values of serum subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α were all found to be lower in the AxSpa patients than in the healthy controls. Furthermore, once the patients were classified regarding their disease activity, no correlation between the study biomarkers and levels of clinical disease indices was observed. Finally, biological treatments were found to affect the serum concentration of these biomarkers regardless of the level of disease activity.
CONCLUSIONS: Novel adipokines and known modulators of inflammation, circulating subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α levels may play a role in assessing treatment efficacy, especially in those treated with TNF-inhibitors. However, we failed to demonstrate a correlation between clinical disease activity and serum biomarker levels.
METHODS: Sixty-one Axial spondyloarthritis (AxSpa) patients and 30 healthy controls were enrolled in the study. The serum biomarkers subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α and the disease indices BASDAI, BASFI, MASES, and ASDAS-ESR/CRP were evaluated and compared. The patients were then classified, and their serum biomarkers were assessed according to their ASDAS scores and their treatment regimens.
RESULTS: Among the studied biomarkers, none showed a significant difference between the patients and the healthy controls. Although the difference was not statistically significant, the median values of serum subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α were all found to be lower in the AxSpa patients than in the healthy controls. Furthermore, once the patients were classified regarding their disease activity, no correlation between the study biomarkers and levels of clinical disease indices was observed. Finally, biological treatments were found to affect the serum concentration of these biomarkers regardless of the level of disease activity.
CONCLUSIONS: Novel adipokines and known modulators of inflammation, circulating subfatin, CTHRC1, CTRP3, CTRP6, IL-6, IL-17, and TNF-α levels may play a role in assessing treatment efficacy, especially in those treated with TNF-inhibitors. However, we failed to demonstrate a correlation between clinical disease activity and serum biomarker levels.
摘要：
背景：该研究旨在研究来自C1qTNF超家族的新型生物标志物，并评估其在自身免疫性炎症性风湿性疾病中的作用，目的是鉴定有效的生物标志物以测量临床疾病活动和评估治疗效果。
方法：研究纳入了61例轴性脊柱关节炎（AxSpa）患者和30例健康对照。血清生物标志物亚脂肪素，CTHRC1，CTRP3，CTRP6，IL-6，IL-17和TNF-α和疾病指标BASDAI，BASFI,MASES,评估并比较ASDAS-ESR/CRP。然后对患者进行分类，根据他们的ASDAS评分和治疗方案评估他们的血清生物标志物。
结果：在研究的生物标志物中，患者和健康对照组之间没有显着差异。尽管差异没有统计学意义，血清亚脂肪素的中值，在AxSpa患者中，CTHRC1，CTRP3，CTRP6，IL-6，IL-17和TNF-α均低于健康对照组。此外，一旦对患者的疾病活动进行了分类，未观察到研究生物标志物与临床疾病指数水平之间的相关性.最后,研究发现,无论疾病活动水平如何,生物治疗都会影响这些生物标志物的血清浓度.
结论：新型脂肪因子和已知的炎症调节剂，循环亚脂肪素，CTHRC1、CTRP3、CTRP6、IL-6、IL-17和TNF-α水平可能在评估治疗疗效方面发挥作用。尤其是那些用TNF抑制剂治疗的患者。然而,我们未能证明临床疾病活动与血清生物标志物水平之间存在相关性.
方法：研究纳入了61例轴性脊柱关节炎（AxSpa）患者和30例健康对照。血清生物标志物亚脂肪素，CTHRC1，CTRP3，CTRP6，IL-6，IL-17和TNF-α和疾病指标BASDAI，BASFI,MASES,评估并比较ASDAS-ESR/CRP。然后对患者进行分类，根据他们的ASDAS评分和治疗方案评估他们的血清生物标志物。
结果：在研究的生物标志物中，患者和健康对照组之间没有显着差异。尽管差异没有统计学意义，血清亚脂肪素的中值，在AxSpa患者中，CTHRC1，CTRP3，CTRP6，IL-6，IL-17和TNF-α均低于健康对照组。此外，一旦对患者的疾病活动进行了分类，未观察到研究生物标志物与临床疾病指数水平之间的相关性.最后,研究发现,无论疾病活动水平如何,生物治疗都会影响这些生物标志物的血清浓度.
结论：新型脂肪因子和已知的炎症调节剂，循环亚脂肪素，CTHRC1、CTRP3、CTRP6、IL-6、IL-17和TNF-α水平可能在评估治疗疗效方面发挥作用。尤其是那些用TNF抑制剂治疗的患者。然而,我们未能证明临床疾病活动与血清生物标志物水平之间存在相关性.
